piperidines has been researched along with Erythema* in 14 studies
3 trial(s) available for piperidines and Erythema
Article | Year |
---|---|
Efficacy and safety of topical Trikatu preparation in, relieving mosquito bite reactions: a randomized controlled trial.
Trikatu is composed of dried fruits of Piper nigrum L and Piper retrofractum Vahl, and dried rhizomes of Zingiber officinale R. Although this preparation has been used to relieve pruritis, pain, and inflammation for a long time, there is no clinical evidence to confirm its efficacy and safety. Therefore, we performed a double-blind, within person-randomized controlled study of 30 healthy volunteers to determine efficacy and safety of topical Trikatu on mosquito bite reactions.. All subjects were bitten by Aedes aegypti laboratory mosquitoes on their forearms and they were randomly assigned arms to apply either Trikatu or reference product on the mosquito bite papule. The main outcome was the difference of papule size reduction at 30 min, measured by a caliper, between the Trikatu and reference arms. Pruritis, redness, pain, and patient satisfaction were assessed at 15, 30, 60, 180, and 360 min as secondary outcomes.. There were no significant differences between treatment and reference arms on any outcome at any time of measurement.. Trikatu did not show additional effects for relieving mosquito bite reaction as compared with the reference product containing camphor, menthol, and eucalyptus. For further study, it is very important to consider a proper selection of subjects, comparator product, and concentration of extract when Trikatu preparation is investigated. Topics: Adult; Aedes; Alkenes; Animals; Erythema; Female; Humans; Insect Bites and Stings; Male; Piperidines; Plant Extracts; Pruritus | 2014 |
Assessment of the wheal size and skin blood flow of the erythema induced by histamine and its modification with cetirizine and ebastine: a crossover, double-blind study.
In order to assess the antihistaminic power of cetirizine and ebastine, we designed a randomized, double-blind, crossover study, measuring their capacity to modify skin blood flow induced by a histamine prick test. The vasomotor response was compared using a laser Doppler flowmeter. Two hours after intake of the antihistaminic drug, there were significant differences between both drugs: at 4 h, the antihistaminic effect of cetirizine persists, whereas ebastine only showed moderate activity. The reduction of the cutaneous blood flow values (CBFV) showed good activity in both groups, but cetirizine was more potent and showed faster activity than ebastine. Topics: Adolescent; Adult; Butyrophenones; Cetirizine; Double-Blind Method; Erythema; Female; Histamine; Histamine H1 Antagonists; Humans; Laser-Doppler Flowmetry; Male; Piperidines; Prospective Studies; Regional Blood Flow; Skin | 1994 |
A clinical comparison of pancuronium with d-tubocurarine.
Topics: Adult; Androstanes; Blood Pressure; Clinical Trials as Topic; Erythema; Female; Halothane; Histamine Release; Humans; Male; Middle Aged; Neuromuscular Nondepolarizing Agents; Nitrous Oxide; Oxygen; Piperidines; Tubocurarine | 1969 |
11 other study(ies) available for piperidines and Erythema
Article | Year |
---|---|
Case Report: Morbihan disease treated with tofacitinib successfully.
To date, there is no standard treatment for Morbihan disease. Several studies have reported that Morbihan disease responds well to systemic corticosteroids (prednisone and prednisolone), systemic antibiotics (tetracyclines), antihistamines (ketotifen) and surgical therapy (Lymphaticovenous anastomosis). To our knowledge, Tofacitinib, as a Janus-activated kinase (JAK) inhibitor, plays a vital role in the treatment of inflammatory and autoimmune disorders. Therefore, Tofacitinib may be a promising medical option for patients with Morbihan disease.. The first case involves a 43-year-old Chinese man who presented a 12-month history of progressive painless swelling of the left upper eyelid. According to the skin biopsy, perivascular dermal edema with dilatation of lymphatic vessels and telangiectasia was observed, accompanied by mixed lymphocyte infiltrate, including histiocytes, plasma cells, and a few eosinophils. The second case involves a Chinese female patient who presented a 2-year history of progressive left-sided facial edema, which was eventually diagnosed as Morbihan disease. The skin biopsy revealed lymphocyte infiltration in the superficial vessels of dermis and some accessories. Based on patients' clinical presentation, skin biopsy results, and exclusion of differential diagnoses such as systemic lupus erythematosus (SLE), they were diagnosed with Morbihan disease. They were both treated with Tofacitinib (5mg, po twice daily).. Patient 1 underwent a trial of Tofacitinib at a dosage of 5 mg twice daily for one month, with notable improvement. His edema and erythema present on the left face were alleviated. Patient 1 reduced the dosage of Tofacitinib by half (5mg, once daily) and continued using it for 5 months. During the 6-month follow-up, the facial erythema in the patient subsided, and there was a noticeable improvement in the swelling of the left eyelid compared to before. Patient 2, her lesions gradually improved after one-week treatment. She received a one-month treatment of Tofacitinib, and during the subsequent six-month follow-up, there was no evidence of eruption recurrence.. We present the first cases of two patients receiving short-term Tofacitinib as therapy for Morbihan disease and retrieving huge succession. Tofacitinib may be a promising oral alternative for patients with Morbihan disease. However, its safety and efficacy require further assessment through clinical trials. Topics: Adult; Anti-Bacterial Agents; Edema; Erythema; Female; Humans; Janus Kinase Inhibitors; Male; Piperidines; Skin | 2023 |
Intense Local Reaction at the Sites of Injection of Lipolytic Mesotherapy.
Topics: Abdomen; Amoxicillin-Potassium Clavulanate Combination; Anti-Inflammatory Agents; Benzimidazoles; Carnitine; Clobetasol; Dermatitis; Edema; Erythema; Female; Humans; Injections, Subcutaneous; Keratosis; Lipolysis; Mesotherapy; Middle Aged; Peptides; Phosphatidylcholines; Piperidines; Prednisone; Subcutaneous Fat; Thigh | 2017 |
MEK inhibitor-induced dusky erythema: characteristic drug hypersensitivity manifestation in 3 patients.
MEK inhibitors are being evaluated in clinical trials for treatment of different malignant neoplasms; trametinib dimethyl sulfoxide was approved by the US Food and Drug Administration for melanoma in 2013. We present 3 cases of patients receiving MEK inhibitors who developed an atypical eruption.. Three patients who were receiving different MEK inhibitors (selumetinib, cobimetinib, and trametinib) developed an eruption, all associated with unique duskiness. Drug hypersensitivity was confirmed by histopathologic testing in 2 of the 3 cases. The skin eruption responded well to corticosteroids and did not recur when treatment with the MEK inhibitor was restarted in 2 of the patients.. The typical skin reaction associated with MEK inhibitors is a papulopustular eruption. To our knowledge, the dusky erythema that occurred in the 3 patients described here has not previously been reported for this drug class. Topics: Adult; Azetidines; Benzimidazoles; Drug Eruptions; Erythema; Female; Glucocorticoids; Humans; Male; Melanoma; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Piperidines; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Skin Neoplasms | 2015 |
A topical matter: toxic epidermal necrolysis.
Topics: Acetaminophen; Analgesics, Opioid; Anti-Inflammatory Agents; Anticonvulsants; Antiemetics; Antineoplastic Agents; Dacarbazine; Dexamethasone; Drug Combinations; Erythema; gamma-Globulins; Glioblastoma; Humans; Immunologic Factors; Levetiracetam; Male; Methylprednisolone; Middle Aged; Omeprazole; Oxycodone; Piperidines; Piracetam; Proton Pump Inhibitors; Quinazolines; Stevens-Johnson Syndrome; Temozolomide; Wound Healing | 2014 |
Hypersensitivity to repaglinide.
Meglitinides (repaglinide and nateglinide) are insulin secretagogues used to treat diabetes mellitus. We present a case of hypersensitivity reaction to repaglinide in a 61-year-old man who developed a maculopapular rash 5 days after treatment. Skin prick tests including repaglinide (0.5 g/mL) and patch tests (0.05% in pet and saline) were performed, and the results were negative. A blind oral challenge test with repaglinide was performed and the therapeutic dose was subsequently taken at home every 24 hours for 7 days. The result was positive with a delayed reaction at day 3. A punch biopsy of the skin lesions revealed drug-induced exanthema. The clinical manifestations, the latency period, the reappearance of cutaneous lesions after rechallenge, and the histopathology report of the skin biopsy suggest a type IV mechanism. Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Hypersensitivity; Erythema; Exanthema; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Patch Tests; Phenylalanine; Piperidines | 2011 |
Correlation between docetaxel-induced skin toxicity and the use of steroids and Hâ‚‚ blockers: a multi-institution survey.
Steroids and H(2) blockers are commonly used as supportive care for taxane-containing chemotherapy, but they also affect docetaxel's primary metabolizer, cytochrome P(450) 3A4. This retrospective observational study was performed to better understand the effects of these compounds on docetaxel-induced skin toxicities, specifically hand-foot syndrome (HFS) and facial erythema (FE), a relationship that is currently poorly understood. Member institutions of the Japan Breast Cancer Research Group were invited to complete a questionnaire on the occurrence of grade 2 or higher HFS and FE among patients treated between April 2007 and March 2008 with docetaxel as an adjuvant or neoadjuvant chemotherapeutic treatment for breast cancer. We obtained data for 993 patients from 20 institutions. Twenty percent received H(2) blockers, and all patients received dexamethasone. Univariate and multivariate analyses revealed that H(2) blockers are associated with a significantly higher incidence of both HFS and FE. The incidence of FE was significantly higher for the docetaxel + cyclophosphamide (TC) regimen than for non-TC regimens combined. Dexamethasone usage did not affect the incidence of either HFS or FE. In conclusion, use of H(2) blockers as premedication in breast cancer patients receiving docetaxel significantly increases the risk of both HFS and FE. Topics: Acetamides; Breast Neoplasms; Chemotherapy, Adjuvant; Dexamethasone; Docetaxel; Erythema; Famotidine; Female; Glucocorticoids; Hand-Foot Syndrome; Histamine H2 Antagonists; Humans; Incidence; Logistic Models; Multivariate Analysis; Neoadjuvant Therapy; Piperidines; Pyridines; Ranitidine; Retrospective Studies; Steroids; Surveys and Questionnaires; Taxoids | 2011 |
Effects and mechanisms of aloperine on 2, 4-dinitrofluorobenzene-induced allergic contact dermatitis in BALB/c mice.
Allergic contact dermatitis is a prototypic T-cell-mediated cutaneous inflammatory response. Multiple cell types, inflammatory mediators and cytokines are involved in the regulation of immunologic and inflammatory processes in allergic contact dermatitis. Aloperine is an isolated alkaloid found in the plant of Sophora alopecuroides L. It has been clinically proved effective in China for a long time for skin inflammatory diseases such as allergic contact dermatitis. However, the mechanism of aloperine on allergic contact dermatitis is largely unknown. Therefore, the aim of this study was to investigate the effect of aloperine on 2, 4-dinitrofluorobenzene (DNFB)-induced allergic contact dermatitis in BALB/c mice and the possible underlying mechanisms. The results showed that topical application of DNFB on the ear provoked typical allergic contact dermatitis with ear swelling and ear erythema in BALB/c mice. Treatments with 1% aloperine suppressed DNFB-induced increase in ear thickness and ear erythema. Moreover, 1% aloperine treatment significantly decreased the up-regulated mRNA and protein levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) induced by DNFB in ear biopsy homogenates. Our findings suggest that aloperine greatly improves the DNFB-induced allergic contact dermatitis in mice. The therapeutic mechanism might be related to the reduction of TNF-alpha, IL-1beta and IL-6 production induced by DNFB. Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Cytokines; Dermatitis, Allergic Contact; Dinitrofluorobenzene; Ear; Erythema; Female; Gene Expression Regulation; Mice; Mice, Inbred BALB C; Piperidines; Quinolizidines; RNA, Messenger | 2010 |
Fixed drug eruption induced by tipepidine hibenzate.
Topics: Antitussive Agents; Child; Drug Eruptions; Erythema; Humans; Japan; Male; Piperidines | 2010 |
Involvement of histamine released from mast cells in acute radiation dermatitis in mice.
A possible involvement of histamine in acute radiation dermatitis in mice was investigated. The dose of 40 Gy of gamma irradiation induced erythema and edema in C57BL/6 mice treated with vehicle. However, in C57BL/6 mice treated with chlorpheniramine and WBB6F1-W/Wv mice, erythema and edema were not observed. In all of these mice, epilation and dry desquamation were induced, but bepotastine significantly reduced the extent of these areas. These results suggest that gamma irradiation-induced erythema and edema were caused by histamine released from mast cells via histamine H1 receptor, and epilation was induced by other inflammatory mediators. Topics: Acute Disease; Animals; Chlorpheniramine; Dose-Response Relationship, Drug; Edema; Erythema; Hair Removal; Histamine; Histamine H1 Antagonists; Histamine Release; Male; Mast Cells; Mice; Mice, Inbred C57BL; Piperidines; Pyridines; Radiodermatitis; Receptors, Histamine H1 | 2007 |
The pharmacology of flazalone: a new class of anti-inflammatory agent.
The anti-inflammatory activity of flazalone, a unique chemical drug, is described. In acute irritant anti-inflammatory tests, flazalone exhibited a wide spectrum of activity. The compound was active in affecting the course of paw swelling in adjuvant arthritis when given daily either at the outset of the polyarthritis or after induction. The most unusual aspect of this compound is its ability to inhibit graft rejection in goldfish and rabbits. The pattern of anti-inflammatory activity does not allow one to classify this drug in the usual groups. Topics: Adrenal Glands; Adrenalectomy; Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Arthus Reaction; Edema; Erythema; Goldfish; Graft Rejection; Graft vs Host Reaction; Guinea Pigs; Hypersensitivity, Delayed; Male; Mice; Passive Cutaneous Anaphylaxis; Piperidines; Rabbits; Rats; Skin Transplantation; Transplantation, Autologous; Transplantation, Homologous | 1976 |
An in vitro and in vivo investigation of the phototoxic effect and its amelioration with radioprotective compounds.
Electron spin resonance spectroscopy has been used to demonstrate that the phototoxic antimalarial drug, 6,8-dichloro-2-phenyl-a-2-piperidnylquinolinemethanol (WR 7930), when irradiated with long-wave ultraviolet (UV) light (lambda greater than 320 nm) while held in a glassy matrix at 73 degrees K, enters a triplet state and releases hydrogen atoms in its environment. The steady-state concentration of triplet WR 7930 molecules and of hydrogen atoms is reduced 2 to 3 times when mercaptoethylamine (MEA) is also present in the UV-irradiated glass. Organosulfur radicals form on MEA while hydrogen atoms and triplet-state molecules are reduced in number. Hydrogen atoms and triplet WR 7930 molecules are considered as mediators of the phototoxicity of the antimalarial drug. Thus, hydrogen atom scavanging and chemical quenching of the triplet state are possible mechanisms by which protection against phototoxic effects could be gained. Protection is demonstrated in mice receiving 20 mg per kg WR 7930 intraperitoneally and exposed to long-wave UV for 20 hr when the radioprotective aminothiol-forming compound, 2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate (WR 2721), is administered at 400 mg per kg immediately before irradiation. When no protective drug is administered concurrently, WR 7930 administration results in intense erythema, edema, and eventual necrosis of ear tissues. Topics: Animals; Antimalarials; Chemical Phenomena; Chemistry; Diamines; Dose-Response Relationship, Drug; Electron Spin Resonance Spectroscopy; Erythema; Female; Free Radicals; Hydrogen; Mercaptoethylamines; Mice; Mice, Inbred Strains; Necrosis; Organothiophosphorus Compounds; Photosensitivity Disorders; Piperidines; Quinolines; Radiation Effects; Radiation-Protective Agents; Ultraviolet Rays | 1975 |